// App-Quantinova.ai

P160/P160 : Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients

Researchers

Presenter

  • K. Allen-Philbey

Principal Investigators

  • S. De Trane

  • A. Stennett

  • O. Yildiz

  • A. Adams

  • B. Turner

  • M. Marta

  • S. Gnanapavan

  • L. Bianchi

  • J. Mathews

  • G. Giovannoni

  • D. Baker

  • K. Schmierer

Medical Centers

  • Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UNITED KINGDOM

  • Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UNITED KINGDOM

  • Pharmacy department, The Royal London Hospital, Barts Health NHS Trust, London, UNITED KINGDOM

  • Pharmacy department, The Royal London Hospital, Barts Health NHS Trust, London, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • Cerebrospinal fluid

  • Neurofilament-light chain

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved